ICML 2023 | Improving risk stratification & treatment decisions for DLBCL: ctDNA & the IPI
Leo Meriranta, MD, University of Helsinki, Helsinki, Finland, discusses the value of the international prognostic index (IPI) risk score in diffuse large B-cell lymphoma (DLBCL). This well-validated prognostic model can be used to determine prognosis and potentially stratify patients for treatment. However, patient heterogeneity remains a challenge. Dr Meriranta comments on the prognostic potential of circulating tumor DNA (ctDNA) levels at diagnosis, which are often associated with IPI risk scores, and explains how this measurement could be used alongside the IPI to further improve the stratification and treatment of patients with DLBCL. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
